EVE Health Group (ASX: EVE) has reached several key milestones in its transition to commercial operations, achieving first patient prescriptions of its Dyspro cannabinoid-based gummy and submitting the initial purchase order for Libbo, an oral dissolving film for erectile dysfunction.
The company also completed a $1.1 million capital raising after the quarter to accelerate rollout of both products, and launched new women’s health education platform Reclaim My Cycle.
EVE said the September quarter marked its shift from development into commercial execution, with both Dyspro and Libbo progressing toward broad market availability.
Dyspro Enters Distribution and Patient Use
During the quarter, EVE completed Good Manufacturing Practice (GMP) manufacture of Dyspro at an Australian-certified facility and began distribution to partner networks, with the product now available for prescription under the Therapeutic Goods Administration’s Special Access Scheme and Authorised Prescriber pathways.
Dyspro targets dysmenorrhoea and endometriosis — two of the most widespread and under-treated women’s health conditions — offering a consistent oral dose form designed for symptom relief and ease of use.
EVE’s rollout strategy includes collaboration with prescribers and clinics, supported by education initiatives designed to improve understanding of women’s health and to build clinical awareness.
The company is focusing on driving early adoption through established medical networks, ensuring consistent supply and clear therapeutic guidance.
Reclaim My Cycle Builds Awareness
Complementing Dyspro’s commercial rollout, EVE launched Reclaim My Cycle, an online platform created to inform and support women managing menstrual pain and endometriosis.
The site offers practical information for patients alongside detailed prescribing resources for healthcare professionals, encouraging open discussion and improved understanding of these conditions.
Reclaim My Cycle is also designed as a channel for ongoing feedback from both clinicians and patients, enabling the company to align future formulations and education efforts with clinical need.
EVE said the platform would form a key pillar in its broader engagement strategy, combining consumer education with prescriber outreach to underpin sustainable product adoption, while also scaling awareness of cannabinoid-based therapies in women’s health.
Libbo Approaches Commercial Launch
EVE also advanced its program for Libbo, confirming the first commercial purchase order during the quarter following completion of all regulatory prerequisites.
Libbo uses EVE’s proprietary dissolving film technology to provide a discreet and fast-acting treatment for erectile dysfunction, addressing a market estimated at more than US$5 billion annually.
A GMP-certified partner will carry out manufacturing, with product set to become availabile for prescription later in 2025.
EVE said its men’s health portfolio would continue to expand in parallel, with supporting programs under development to build long-term engagement and prescriber familiarity.
Scientific Advisory Board Strengthens Oversight
EVE established a Scientific Advisory Board during the quarter to provide independent oversight across its therapeutic pipeline.
The inaugural appointment was Dr Fiona Cousins, senior research scientist at the Hudson Institute of Medical Research, who brings expertise in reproductive and women’s health.
The board will guide EVE’s ongoing R&D programs, ensuring clinical robustness and alignment with evolving medical standards.
EVE said the board will also play an advisory role in future studies supporting full Therapeutic Goods Administration registration, and expects to make additional appointments in coming quarters as the company progresses new product formulations and regulatory submissions.
